XML 21 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues:    
Revenues $ 43,000 $ 420,000
Operating expenses:    
Research and development 6,655,000 19,155,000
General and administrative 5,392,000 6,718,000
Total operating expenses 12,047,000 25,873,000
Operating loss (12,004,000) (25,453,000)
Other expense:    
Foreign exchange losses (54,000) (414,000)
Interest income 12,000 266,000
Other income, net 52,000 50,000
Total other income (expense), net 10,000 (98,000)
Loss before taxes (11,994,000) (25,551,000)
Income tax benefit 782,000 2,996,000
Net loss (11,212,000) (22,555,000)
Dividend on convertible exchangeable preferred shares 0 (201,000)
Net loss applicable to common shareholders $ (11,212,000) $ (22,756,000)
Basic and diluted earnings per common share:    
Net loss per share - basic $ (2.09) $ (26.75)
Net loss per share - diluted $ (2.09) $ (26.75)
Clinical trial supply    
Revenues:    
Revenues $ 43,000 $ 420,000